To include your compound in the COVID-19 Resource Center, submit it here.

BMS reports mixed Phase III data for Opdivo/Yervoy combo in first-line RCC

Bristol-Myers Squibb Co. (NYSE:BMY) reported mixed top-line data from the Phase III CheckMate -214 trial evaluating Opdivo nivolumab (BMS-936558, MDX-1106, ONO-4538) plus Yervoy ipilimumab in about 1,070 previously untreated, intermediate- and

Read the full 316 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE